One of the most recent developments in the public health sector is the tendency to increase the aging population. In the United States, predictions indicate that by 2025 the number of people over 65 years will be doubled, proportional to the problems of that life.
Our country is related to this trend. In the last National Census (2010) Argentina has six million people (14% of the population) in 60 years. This group is in the organized sector of the country. The highest percentage of senior citizens in this sector.
As we take into account that the diagnosis of dementia, especially Alzheimer's disease worldwide, is an epidemic worldwide, the maximal effort of researchers is to maximize the risk of suffering today. You can stop them.
The last findings of Alzheimer's have been confirmed PostmortemIn recent years, treatment and early detection have been developed. The changes in the brain cells associated with the early stages of dementia can be found in the new Laboratory of Publu Scandelier and Aman Mann in the laboratory of Erki Rüsseli in the University of California, San Diego, United States.
The PhD in Mendoza, Argentina, was studied. CTGF (Connective Tissue Growth Factor), in the early stages of Alzheimer's, finds proteins stored in the circular wall of blood vessels.
"CTF Protein begins to collect cerebral blood vessels even before the formation of beta-ammonium platelets, Alzheimer's disease is normal," Scudeller explains. This is a nice tip to leave the ball
Published article Nature Communication It also describes a small chain of amino acids called a "DAG" or a peptide. The digestive tract can be injected into the bloodstream, which searches for faster partner CTGF.
Diagnosis is very important. Because DAG can provide small particles of iron oxide, a thousand times smaller than cells, to the affected area. The intimacy of these particles varies in magnetic resonance tomography, and it helps doctors and researchers find and define the scope of disorders. For Scandelier, DAG can detect Alzheimer's disease much earlier than clinical use approved contract agents.
Not only is a partner for diagnosis but also a DAG peptide taken not only therapeutic drug.
"Now that you have CTGF designed to connect a major site in this protein, it will remove the functionality or you can develop an antibody to prevent it," says Scudeller. "Another treatment is to integrate the synthetic organs of CTGF, blood vessels, astrocytes, and brain cells in the cells.
Another important aspect of discovery is the CTGF in blood vessels, which means it will provide any kind of medical or diagnostic compound involved in blood related to blood. "Tissue does not penetrate or penetrate into the cell, it's hard to achieve," Skroweller continued.
The researchers have analyzed the mouse on mouse mice. DAG "The presence of CTGF in the early stage of diagnosis opens with diagnosis and treatment." Scudeller says, "Alzheimer's disease appears in the bloodstream of the brain before the metabolic mental problems in the CTGF brain."
Pepeptant patented, and Scoddeller was selected to continue research in the University of Tartu in Endowia. But the San Diego team will get this goal (CGGF peptides, small molecules or antibodies, or improving diagnosis or a treatment response.
They set up a biotechnology company (AivoCode, https://aivocode.com) that owns the patent license. The ECC is also a pioneer in the development of innovative technology and a broader platform for testing and treatment of neurological diseases.
The findings of this study are encouraging. Alzheimer's disease is a disease of the patient and the family, no one should be careless.
A pathology with great social consequences
Third in sociology costs is ecemic heart disease and cancers affected. Alzheimer's disease is a growing global disease. According to official statistics, 0.5% of the world's population lives with dimensia today. About 36 million people suffer from present-day bouts and 115 million people by 2050.
In Germany, the birth rate of dementia is 12.2 percent of those over the age group of 65 years. According to these estimates, we have more than 600,000 people in the country of dementia. About 60 percent of these are Alzheimer's type (360,000 topics). Population impact will be greater if we add individuals who offer patient and care.
In the economy, this disease is very large. According to official predictions, this is being spent on organizing the world and a trillion dollars by the end of the year.
See the abnormalities of the patient's brain
When observed in microscopic tissue, Alzheimer's patient's brain tissue appreciates the two types of abnormalities described as character traits. They say:
They say that "beta-ammovid" is a protein source and it destroys brain neurons. Although the ultimate goal of the death of neurons is unknown, the collection of beta-amoietites outside the brain cells is a major suspect.
Neurons also depend on an international transportation and support system that transports nutrients and other necessities in the long run. This system requires the structure and normal operation of the "to" protein.
Alzheimer's disease, the thread proteins in the tow protein distort the real nuisance in the brain cells, which is why the system of system failure and another factor responsible for the death of neurons.
(*) Neuro sciences
The original entry of this article was published in our print edition on 11/26/2018.